News
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.
Hosted on MSN11m
Is Viking's Growth Still Worth the Premium?
Viking (NYSE: VIK) stock is down approximately 3% after the cruise line's second-quarter earnings report. The company ...
Viking Holdings Ltd (NYSE: VIK) shares slipped despite strong Q2 results and positive analyst outlook. Pricing power and ...
Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...
The modern Viking diet emphasizes whole foods over ultraprocessed options, with experts recommending home cooking and ...
I don't go on Carnival expecting it to be Viking. Even Royal Caribbean is really different from Celebrity even though they ...
Viking Holdings Ltd. shares fell as the cruise line operator is facing constraints on how much it can charge for its journeys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback